Abstract
Background: Approximately two-thirds of patients with depression experience physical pain symptoms. Coexisting pain complicates the treatment of depression and is associated with worse depression outcomes. Objective: The authors reviewed the effect of newer antidepressants on pain in patients with depression. Method: The authors searched systematically for trials of second-generation antidepressants that enrolled depression patients and reported pain outcomes, pooling changes on the pain visual-analog scale (VAS), using random-effects models. Results: Eight trials were eligible. Pooled analysis of head-to-head trials showed no difference in VAS between duloxetine and paroxetine. Both drugs were superior to placebo. Conclusion: The authors found insufficient evidence to support the choice of one second-generation antidepressant over another in patients with pain accompanying depression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 191-198 |
| Number of pages | 8 |
| Journal | Psychosomatics |
| Volume | 49 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2008 |
Bibliographical note
Funding Information:Dr. Krebs was supported by the Robert Wood Johnson Clinical Scholars Program . Dr. Gaynes was supported in part by an NIMH K23 Career Development Award ( MH01951-03 ), and Dr. Hansen was supported by NIH grant K12 RR023248 .
Funding Information:
This research was funded through a contract from the Agency for Healthcare Research and Quality to the RTI International University of North Carolina Evidence-Based Practice Center (contract #290–02-0016 ).